Last reviewed · How we verify
Poisoning by digitalis glycoside — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Lanoxin | digoxin | Generic (originally Burroughs Wellcome/GSK) | Cardiac Glycoside [EPC] | Nuclear receptor ROR-gamma, Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2 | 1954-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Burroughs Wellcome/GSK) · 1 drug in Poisoning by digitalis glycoside
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Poisoning by digitalis glycoside:
- Poisoning by digitalis glycoside treatment updates — RSS
- Poisoning by digitalis glycoside treatment updates — Atom
- Poisoning by digitalis glycoside treatment updates — JSON
Cite this brief
Drug Landscape (2026). Poisoning by digitalis glycoside — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/poisoning-by-digitalis-glycoside. Accessed 2026-06-10.
Related
- Poisoning by digitalis glycoside full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing